thecardiologyadvisor.com10h
FDA Extends Review of Elamipretide for Barth Syndrome
The FDA has extended the review period for the New Drug Application for elamipretide for the treatment of Barth syndrome.
ophthalmologytimes13h
Viralgen and Axovia Therapeutics partner to manufacture gene therapy for Bardet-Biedl Syndrome
The companies will work together by using the codon-optimized BBS1 AAV9 vector to minimize the vision loss caused by the ...
Healio11h
Chronic HBV treatment with xalnesiran plus immunomodulator confers highest HBsAg loss
Treatment with xalnesiran, a small interfering RNA molecule, plus an immunomodulator resulted in hepatitis B surface antigen loss among adults with chronic HBV infection, according to a study ...